Physician profile
Caitlin E Cuffney
NPI 1235505264
$2,425.25
in general payments reported to CMS, 2019-2025
26 companies · $731 in 2025
The $731 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.53 · 2022: $131 · 2023: $677 · 2024: $869 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $399.91 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $329.34 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $294.57 | 2022-2025 | Mounjaro, Trulicity, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.63 | 2023-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Pfizer INC. | $180.40 | 2023-2025 | |
| Amgen INC. | $119.30 | 2023-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $117.55 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $101.59 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $95.46 | 2023-2025 | Eliquis, Camzyos |
| Dexcom, INC. | $72.42 | 2024-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $67.48 | 2024-2025 | |
| Baxter Healthcare | $59.81 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Phathom Pharmaceuticals, INC. | $55.17 | 2024 | Voquezna |
| Abbott Laboratories | $48.05 | 2024-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $45.64 | 2024 | Gardasil 9, Capvaxive, Gardasil |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.39 | 2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $30.28 | 2023-2024 | |
| Vbi Vaccine (Delaware) INC. | $30.28 | 2022 | |
| Edwards Lifesciences Corporation | $28.37 | 2024 | Sapien 3 Ultra Resilia |
| Indivior INC. | $20.36 | 2023 | Sublocade |
| Novartis Pharmaceuticals Corporation | $18.00 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $17.59 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.53 | 2021 | |
| Verona Pharma, INC. | $16.39 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $14.94 | 2023 | Nuzyra |
| Vivaquant INC, Dba Rhythm Express | $9.80 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Cuffney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.